Developing new treatments for a type of leukemia linked to MLL gene rearrangements
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias
This study is looking at a type of leukemia that affects babies and is testing a new treatment that targets a specific protein to help fight the cancer more effectively, especially for those who haven't had much success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11066502 on NIH RePORTER |
What this research studies
This research focuses on a specific type of leukemia caused by rearrangements of the MLL gene, which is particularly prevalent in infants. The study aims to develop a novel therapeutic strategy using WDR5 PROTACs, which are designed to degrade the WDR5 protein that plays a crucial role in the growth of these cancer cells. By targeting WDR5, the researchers hope to create a more effective treatment option for patients who currently have limited responses to existing therapies. The approach involves pharmacological degradation rather than traditional inhibition, which may lead to better outcomes for patients with MLL-rearranged leukemias.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants and children diagnosed with acute lymphoblastic leukemia or acute myeloid leukemia characterized by MLL gene rearrangements.
Not a fit: Patients with other types of leukemia or those who do not have MLL gene rearrangements may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from MLL-rearranged leukemias.
How similar studies have performed: While the approach of targeting WDR5 is novel, previous research has shown promise in targeting similar pathways in cancer treatment.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Jin, Jian — Icahn School of Medicine at Mount Sinai
- Study coordinator: Jin, Jian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.